Survodutide – 10mg

Survodutide

Product is sold for prescriber purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

Survodutide (BI 456906) is a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed for the treatment of obesity and type 2 diabetes. Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.(link.springer.com)

In diet-induced obese (DIO) mice, survodutide administration resulted in significant body weight reduction, comparable to or exceeding that of selective GLP-1R agonists. The compound also improved oral glucose tolerance and increased markers associated with energy expenditure, such as fibroblast growth factor 21 (FGF21) and hepatic nicotinamide N-methyltransferase (NNMT) mRNA expression. (pubmed.ncbi.nlm.nih.gov)

Further studies have shown that survodutide’s dual agonism leads to enhanced metabolic benefits. In diabetic db/db mice, survodutide treatment significantly lowered glycated hemoglobin levels, indicating improved glycemic control. The compound’s balanced activation of GCGR and GLP-1R pathways contributes to its robust anti-obesity and antidiabetic effects. (pubmed.ncbi.nlm.nih.gov)

A meta-analysis of clinical trials involving survodutide reported significant reductions in body weight, body mass index (BMI), and waist circumference among participants. Longer treatment durations and higher doses were associated with more pronounced effects, suggesting dose-dependent efficacy. (dmsjournal.biomedcentral.com)

The pharmacological profile of survodutide, including its half-life extension through lipidation, allows for once-weekly dosing, enhancing patient compliance. Its dual receptor activity addresses multiple metabolic pathways, making it a promising candidate for comprehensive obesity and diabetes management. (researchgate.net)

In conclusion, survodutide’s dual GCGR/GLP-1R agonism offers a multifaceted approach to treating metabolic disorders. Its efficacy in preclinical models supports further investigation and development as a therapeutic agent for obesity and type 2 diabetes.(researchgate.net)

References

1. Le Roux, Carel W., et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet Diabetes & Endocrinology, vol. 12, no. 3, 2024, pp. 162-173. https://pubmed.ncbi.nlm.nih.gov/38330987/
2. Zimmermann, Tina, et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes, Obesity and Metabolism, vol. 26, no. 1, 2024, pp. 1-12. https://pubmed.ncbi.nlm.nih.gov/38560764/
3. “Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: A meta-analysis.” Diabetology & Metabolic Syndrome, vol. 16, 2024, article 501. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-024-01501-x
4. Klein, Thomas, et al. “Perspectives in weight control in diabetes – Survodutide.” Diabetes Research and Clinical Practice, vol. 203, 2023, article 110123. https://www.sciencedirect.com/science/article/abs/pii/S0168822723005429
5. “Dose–response effects on HbA1c and bodyweight reduction of survodutide in type 2 diabetes: A phase II study.” Diabetologia, vol. 66, no. 1, 2023, pp. 53-65. https://link.springer.com/article/10.1007/s00125-023-06053-9